Your browser doesn't support javascript.
loading
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity.
Ramalingam, Nagendran; Jin, Shan-Xue; Moors, Tim E; Fonseca-Ornelas, Luis; Shimanaka, Kazuma; Lei, Shi; Cam, Hugh P; Watson, Aurelia Hays; Brontesi, Lisa; Ding, Lai; Hacibaloglu, Dinc Yasat; Jiang, Haiyang; Choi, Se Joon; Kanter, Ellen; Liu, Lei; Bartels, Tim; Nuber, Silke; Sulzer, David; Mosharov, Eugene V; Chen, Weisheng V; Li, Shaomin; Selkoe, Dennis J; Dettmer, Ulf.
Afiliación
  • Ramalingam N; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. nramalingam@bwh.harvard.edu.
  • Jin SX; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Moors TE; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Fonseca-Ornelas L; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Shimanaka K; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Lei S; Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.
  • Cam HP; Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.
  • Watson AH; UK Dementia Research Institute, University College London, London, UK.
  • Brontesi L; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Ding L; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Hacibaloglu DY; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Jiang H; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Choi SJ; Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.
  • Kanter E; Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.
  • Liu L; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Bartels T; UK Dementia Research Institute, University College London, London, UK.
  • Nuber S; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
  • Sulzer D; Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.
  • Mosharov EV; Departments of Neurology and Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.
  • Chen WV; Department of Molecular Therapeutics and Pharmacology, Columbia University Medical Center, New York, NY, 10032, USA.
  • Li S; Division of Molecular Therapeutics, New York State Psychiatric Institute, Research Foundation for Mental Hygiene, New York, NY, 10032, USA.
  • Selkoe DJ; Departments of Neurology and Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.
  • Dettmer U; Leveragen, Inc., 17 Briden Street, Worcester, MA, 01605, USA.
NPJ Parkinsons Dis ; 9(1): 4, 2023 Jan 16.
Article en En | MEDLINE | ID: mdl-36646701
In Parkinson's disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA-/- neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Parkinsons Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Parkinsons Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos